Aquila’s pre-clinical core services focus on Immuno-Oncology, Immunology and Multiplex Histology services with therapeutic relevance for Oncology, Biomarker Discovery and Target Expression, covering a wide range of in vitro and in vivo proof-of-concept studies.
Services investigating the effects of novel compounds provide high-value data to define both compound efficacy and mechanism of action, speeding up and enhancing your drug discovery pipeline. The company designs bespoke in vitro immune cell-based assays, in conjunction with client objectives, to focus on target pathways and potentially identify clinical relevance in the immuno-oncology arena.
Aquila works closely with our clients to understand their scientific questions, and will tailor services specifically to meet the objectives of the project. If required, Aquila will conduct assay development and validation work upfront of compound screening to ensure the platform is robust and will deliver the desired outcome for our client. We are very focussed on delivering a superior quality service, with high attention to detail, and believe the pre-clinical services Aquila provides offer a time-efficient, cost-effective outsourcing solution that increases the success of lead candidates on the path to the clinic.